These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer. Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118 [TBL] [Abstract][Full Text] [Related]
26. Enhancer identification in mouse embryonic stem cells using integrative modeling of chromatin and genomic features. Chen CY; Morris Q; Mitchell JA BMC Genomics; 2012 Apr; 13():152. PubMed ID: 22537144 [TBL] [Abstract][Full Text] [Related]
27. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Lovén J; Hoke HA; Lin CY; Lau A; Orlando DA; Vakoc CR; Bradner JE; Lee TI; Young RA Cell; 2013 Apr; 153(2):320-34. PubMed ID: 23582323 [TBL] [Abstract][Full Text] [Related]
29. 3D genomic analysis reveals novel enhancer-hijacking caused by complex structural alterations that drive oncogene overexpression. Mortenson KL; Dawes C; Wilson ER; Patchen NE; Johnson HE; Gertz J; Bailey SD; Liu Y; Varley KE; Zhang X Nat Commun; 2024 Jul; 15(1):6130. PubMed ID: 39033128 [TBL] [Abstract][Full Text] [Related]
30. Gene Transactivation and Transrepression in MYC-Driven Cancers. Scafuro M; Capasso L; Carafa V; Altucci L; Nebbioso A Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801599 [No Abstract] [Full Text] [Related]
31. A dynamic exchange of TCF3 and TCF4 transcription factors controls MYC expression in colorectal cancer cells. Shah M; Rennoll SA; Raup-Konsavage WM; Yochum GS Cell Cycle; 2015; 14(3):323-32. PubMed ID: 25659031 [TBL] [Abstract][Full Text] [Related]
32. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells. Wang J; Boxer LM J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498 [TBL] [Abstract][Full Text] [Related]
34. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515 [TBL] [Abstract][Full Text] [Related]
35. Transcriptional amplification in tumor cells with elevated c-Myc. Lin CY; Lovén J; Rahl PB; Paranal RM; Burge CB; Bradner JE; Lee TI; Young RA Cell; 2012 Sep; 151(1):56-67. PubMed ID: 23021215 [TBL] [Abstract][Full Text] [Related]
36. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits. Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659 [TBL] [Abstract][Full Text] [Related]
37. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets. Bacabac M; Xu W Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907 [TBL] [Abstract][Full Text] [Related]
38. A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma. Hu HM; Arcinas M; Boxer LM J Biol Chem; 2002 Mar; 277(12):9819-24. PubMed ID: 11777933 [TBL] [Abstract][Full Text] [Related]
39. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis. Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402 [TBL] [Abstract][Full Text] [Related]
40. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Lockwood WW; Zejnullahu K; Bradner JE; Varmus H Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]